Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $46.2857.

A number of research analysts recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating and set a $52.00 price target on shares of Zenas BioPharma in a research report on Monday, October 27th. Evercore ISI assumed coverage on shares of Zenas BioPharma in a report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 target price for the company. Citigroup boosted their price target on Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. HC Wainwright upped their price target on Zenas BioPharma from $30.00 to $44.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Zenas BioPharma in a research note on Thursday, October 30th.

Insiders Place Their Bets

In related news, Director Jason Raleigh Nunn bought 63,158 shares of the business’s stock in a transaction on Thursday, October 9th. The stock was acquired at an average price of $19.00 per share, with a total value of $1,200,002.00. Following the transaction, the director owned 1,173,395 shares in the company, valued at approximately $22,294,505. This trade represents a 5.69% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Patrick G. Enright bought 105,265 shares of the firm’s stock in a transaction that occurred on Thursday, October 9th. The stock was bought at an average cost of $19.00 per share, for a total transaction of $2,000,035.00. Following the completion of the acquisition, the director owned 1,832,669 shares in the company, valued at $34,820,711. This trade represents a 6.09% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 923,035 shares of company stock worth $17,628,163 in the last quarter. Insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Quarry LP grew its stake in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Zenas BioPharma in the 3rd quarter worth approximately $30,000. BNP Paribas Financial Markets boosted its stake in Zenas BioPharma by 120.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Zenas BioPharma by 41.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after purchasing an additional 2,679 shares during the last quarter. Finally, Sei Investments Co. acquired a new position in Zenas BioPharma during the 2nd quarter valued at approximately $118,000.

Zenas BioPharma Trading Down 19.7%

ZBIO stock opened at $32.59 on Tuesday. The company has a market capitalization of $1.75 billion, a PE ratio of -4.61 and a beta of -1.62. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. Zenas BioPharma has a one year low of $5.83 and a one year high of $41.50. The company’s 50 day moving average price is $32.62 and its two-hundred day moving average price is $21.20.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.